Karbicombi

Hydrochlorothiazide and Candesartan cilexetil, the active ingredients in Karbicombi, are a thiazide diuretic and an angiotensin II receptor blocker presented as an oral tablet for oral use. The combination is indicated for the management of hypertension in adult patients.

GNH USA supplies Karbicombi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards, is manufactured under strict GMP conditions, and is distributed to a broad network of healthcare providers across multiple regions.

Karbicombi is used to treat hypertension, a condition characterized by elevated arterial pressure. - Essential hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. - Renal‑associated hypertension: improves blood pressure control in patients with mild to moderate renal impairment. - Hypertension in elderly patients: provides effective blood pressure reduction with a convenient once‑daily oral regimen.

Karbicombi may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Dizziness - Headache - Increased urination - Electrolyte imbalance (e.g., low potassium) - Fatigue - Cough

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Acute kidney injury - Hyperkalemia - Pancreatitis - Liver function abnormalities - Blood dyscrasias (e.g., agranulocytosis)

Before prescribing Karbicombi, clinicians should consider several precautionary measures to ensure patient safety. - Monitor electrolytes: check serum potassium and sodium regularly, especially after therapy initiation. - Assess renal function: evaluate creatinine clearance before and during treatment. - Use caution in diabetes: antihypertensive effect may mask hypoglycaemia symptoms. - Avoid in severe hepatic impairment: drug metabolism may be altered. - Review concomitant NSAID use: may reduce diuretic efficacy and affect renal function. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Karbicombi can interact with other medicines, and some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Aliskiren (especially in diabetic patients): risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors or other ARBs: additive effect on potassium and renal function. - Lithium: increased lithium levels leading to toxicity. - NSAIDs (high dose): may diminish antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, calcium channel blockers): may cause excessive blood pressure reduction. - Antidiabetic agents (insulin, sulfonylureas): may need dose adjustment due to improved glycaemic control. - Corticosteroids: may increase sodium retention counteracting diuretic effect. - Digoxin: monitor serum levels as electrolyte changes can affect toxicity.